Payment(s) received for milestone payments associated with a collaborative agreement.

No definition available.

Name:	aciu_CollaborativeAgreementMilestonePaymentReceived
Namespace Prefix:	aciu_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Period of time that notice is required to be given for cancellation of the collaborative agreement contract, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.

+ References

No definition available.

+ Details

Name:	aciu_CollaborativeAgreementNoticeOfContractTerminationPeriod
Namespace Prefix:	aciu_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

The total potential value of the collaborative agreement.

+ References

No definition available.

+ Details

Name:	aciu_CollaborativeAgreementPotentialValue
Namespace Prefix:	aciu_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Collaborative agreement, upfront payments received

+ References

No definition available.

+ Details

Name:	aciu_CollaborativeAgreementUpfrontPaymentsReceived
Namespace Prefix:	aciu_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- References

No definition available.

+ Details

Name:	ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract
Namespace Prefix:	ifrs-full_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

The amount of revenue from contracts with customers. A customer is a party that has contracted with an entity to obtain goods or services that are an output of the entity’s ordinary activities in exchange for consideration.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 15
-IssueDate 2021-01-01
-Paragraph 113
-Subparagraph a
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2021-en-r&anchor=para_113_a&doctype=Standard
-URIDate 2021-03-24

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 15
-IssueDate 2021-01-01
-Paragraph 114
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2021-en-r&anchor=para_114&doctype=Standard
-URIDate 2021-03-24

+ Details

Name:	ifrs-full_RevenueFromContractsWithCustomers
Namespace Prefix:	ifrs-full_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

The amount of the transaction price allocated to the performance obligations that are unsatisfied (or partially unsatisfied) as of the end of the reporting period. The transaction price is the amount of consideration to which an entity expects to be entitled in exchange for transferring promised goods or services to a customer, excluding amounts collected on behalf of third parties (for example, some sales taxes). [Refer: Performance obligations [member]]

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 15
-IssueDate 2021-01-01
-Paragraph 120
-Subparagraph a
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2021-en-r&anchor=para_120_a&doctype=Standard
-URIDate 2021-03-24

+ Details

Name:	ifrs-full_TransactionPriceAllocatedToRemainingPerformanceObligations
Namespace Prefix:	ifrs-full_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Details

Name:	ifrs-full_TypesOfContractsAxis=aciu_CollaborationAgreementOf2014JanssenPharmaceuticalsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	ifrs-full_ProductsAndServicesAxis=aciu_TauVaccineInADMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Contract revenues, Tau Vaccine in AD - 2014 Agreement with Janssen Pharmaceuticals (Details) - CHF (SFr) SFr in Thousands	1 Months Ended				12 Months Ended
	Dec. 31, 2022	May 31, 2016	Dec. 31, 2014	May 31, 2014	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Contract revenues
Revenue from contracts with customers					SFr 3,935	SFr 0	SFr 15,431
2014 Agreement with Janssen Pharmaceuticals [Member]
Contract revenues
Revenue from contracts with customers					SFr 0	0	1,083
Tau Vaccine in AD [Member] \| 2014 Agreement with Janssen Pharmaceuticals [Member]
Contract revenues
Period to provide notice of termination of agreement					90 days
Milestone payment received		SFr 4,900
Revenue from contracts with customers			SFr 25,900	SFr 4,900	SFr 0	SFr 0	SFr 1,100
Collaborative agreement, upfront payments received	SFr 25,900
Tau Vaccine in AD [Member] \| 2014 Agreement with Janssen Pharmaceuticals [Member] \| Minimum
Contract revenues
Total potential collaboration agreement value remaining	458,000				458,000
Tau Vaccine in AD [Member] \| 2014 Agreement with Janssen Pharmaceuticals [Member] \| Maximum
Contract revenues
Total potential collaboration agreement value	SFr 500,000				SFr 500,000